GENOVA, Inc. Revises Earnings Forecast — Net Profit Down 34%
GENOVA, Inc. (TSE:9341) has revised its full-year earnings forecast for the fiscal year ending March 2026, citing M&A integration headwinds and tax accounting adjustments that will significantly pressure bottom-line profitability despite higher revenue.
| Item | Before | After | Change |
|---|---|---|---|
| 連結売上高 | JPY 11.3bn | JPY 11.6bn | +2.1% |
| 連結営業利益 | JPY 477M | JPY 400M | -16.1% |
| 連結経常利益 | JPY 482M | JPY 432M | -10.4% |
| Net Profit | — | — | — |
| １ 株 当 た り 連結当期純利益 | JPY 24M | JPY 16M | -34.1% |
The company acquired dental distribution business Kabushiki Kaisha ASANO in July 2025, which expanded consolidated revenue by JPY 233M to JPY 11.6bn. However, the acquired unit operates at lower gross margins than GENOVA’s core operations, and post-merger integration cost-reduction initiatives remain in progress. Additionally, the company will record a deferred tax asset write-down and tax adjustment charges following a reassessment of tax classification, further depressing net profit to JPY 275M from the prior forecast of JPY 417M. Separately, GENOVA’s medical platform business faced slower page-view growth in the first half, though content expansion efforts triggered a recovery trajectory in the fourth quarter that fell short of offsetting earlier weakness.
Despite the 34% decline in net profit per share to JPY 15.89/share, management maintained its year-end dividend forecast at JPY 30/share, signaling confidence in medium-term business recovery. Investors should monitor the pace of margin improvement at the acquired dental distribution unit and the sustainability of the medical platform’s rebound as key indicators of execution risk.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.